Drug

Platinum

In clinical development

Emerging researchLate-stage developmentRising momentum

RxNorm1311280 ChEMBLCHEMBL1235478UNII49DFR088MY

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations

Clinical trial2026-07-06Results expected Q2 2027 · ClinicalTrials.gov

A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

Clinical trial2026-06-29Results expected Q2 2029 · ClinicalTrials.gov

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)

Clinical trial2026-05-11Results posted · ClinicalTrials.gov

Clinical trial2026-03-31Primary completion · ClinicalTrials.gov

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Clinical trial2026-03-30Completed · ClinicalTrials.gov

A Phase II Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Combination With Platinum-Based Chemotherapy With or Without Bevacizumab in Patients With Advanced Cervical Cancer

Clinical trial2026-03-27Results expected Q4 2027 · ClinicalTrials.gov

An Open, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Clinical trial2025-12-09Results expected Q2 2027 · ClinicalTrials.gov

Single-Step Patterning of Biocompatible Neural Electrodes Using Black-Pt Functionalized Laser-Induced Graphene for in Vivo Electrophysiology.

Research2025-09-18Small methods

Elevating Platinum to Volumetric Capacitance: High Surface Area Electrodes through Reactive Pt Sputtering.

Research2024-05-27Advanced healthcare materials

Wired for Success: Probing the Effect of Tissue-Engineered Neural Interface Substrates on Cell Viability.

Research2024-05-09ACS biomaterials science & engineering

A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.

Research2024-04-01Clinical cancer research : an official journal of the American Association for Cancer Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Platinum

RxNorm CUI

1311280

ChEMBL ID

CHEMBL1235478

UNII

49DFR088MY

Clinical trials

25 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 25

Phase 14Phase 1 / 23Phase 211Phase 35Phase 42

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Not yet recruitingPH IVChina Medical University, Chinan=312027

Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Unknown statusPH IVQilu Hospital of Shandong Universityn=2502017

A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurrent Chemoradiotherapy With Short-term Adjuvant Chemotherapy Versus Platinum-based Monotherapy Concurrent Chemoradiotherapy in Patients With Postoperative Cervical Gastric-type Adenocarcinoma With High-risk Factors for Recurrence.

Not yet recruitingPH IIIWomen's Hospital School Of Medicine Zhejiang Universityn=2382030

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients: A Prospective, Multicenter Clinical Trial

RecruitingPH IIIChinese Academy of Medical Sciencesn=3002027

A Randomized Phase III Comparing Sequential Therapy With Induction Chemotherapy/Chemoradiation To Cisplatinum-Based Chemoradiotherapy in Locally Advanced Hypopharyngeal Carcinoma

Unknown statusPH IIISun Yat-sen Universityn=1602025

Recent completions

Trials that read out recently, adding to the completed evidence base.

CompletedPH I/IITakedan=2482026

A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

CompletedPH IBristol-Myers Squibbn=122024

CompletedPH IIIInnovent Biologics (Suzhou) Co. Ltd.n=3972022

A Phase IIa Exploratory Study of OCZ103-OS in Combination With Platinum-Gemcitabine Based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients

CompletedPH IIOncozyme Pharma Inc.n=252014

Multicentric Randomized Phase III Study Comparing Gefitinib Versus Platinum-Based Chemotherapy In EGFR Fish Positive NSCLC Patients (Range)

CompletedPH IIIFondazione Humanitas per la Ricercan=12010

Research activity

17 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20172025

Most influential

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

The New England journal of medicine · 2017 · 2,677 cites

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 505 cites

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.

Nature communications · 2020 · 282 cites

Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.

Journal of experimental & clinical cancer research : CR · 2022 · 235 cites

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

JAMA oncology · 2021 · 233 cites

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 188 cites

Related diseases

4 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Lung Neoplasms8 Carcinoma, Non-Small-Cell Lung7 Ovarian Neoplasms3 Carcinoma, Ovarian Epithelial2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Pembrolizumab

Studied across 6 of the same disease areas as Platinum in the shared literature.

6 shared diseases2 shared papers

Camptothecin

Studied across 5 of the same disease areas as Platinum in the shared literature.

5 shared diseases2 shared papers

Sacituzumab govitecan

Studied across 5 of the same disease areas as Platinum in the shared literature.

5 shared diseases1 shared paper

Pemetrexed

Studied across 2 of the same disease areas as Platinum in the shared literature.

2 shared diseases2 shared papers

Ceralasertib

Studied across 3 of the same disease areas as Platinum in the shared literature.

3 shared diseases1 shared paper

Durvalumab

Studied across 3 of the same disease areas as Platinum in the shared literature.

3 shared diseases1 shared paper

Osimertinib

Studied across 3 of the same disease areas as Platinum in the shared literature.

3 shared diseases1 shared paper

Patritumab deruxtecan

Studied across 3 of the same disease areas as Platinum in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials